Status:
COMPLETED
Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults
Lead Sponsor:
Novartis Vaccines
Conditions:
Helicobacter Pylori
Gastritis
Eligibility:
All Genders
18-40 years
Phase:
PHASE1
Brief Summary
This study was designed to investigate the safety and immunogenicity of Chiron's investigational H. pylori (HP3) vaccine
Eligibility Criteria
Inclusion
- Healthy
- Ages 18-40
- Negative for H. pylori infection
- Contraception for females
Exclusion
- Present or past H. pylori infection
- Medically significant gastroduodenal disease
- Recent corticosteroid use
- Bleed diathesis
- Use of antibiotics used to treat H. pylori infection
Key Trial Info
Start Date :
February 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2002
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT00613665
Start Date
February 1 2001
End Date
April 1 2002
Last Update
June 11 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitaetsklinikum Charité
Berlin, Germany, 10117